Nurse Practitioner Program year 2023 Source: CMS Open Payments, 2026 publication

Kemble Green

Nurse Practitioner, Gerontology Clackamas, OR Nurse Practitioner

NPI 1205292703 CMS profile 10495095

10365 Se Sunnyside Rd Ste 340, Clackamas, OR 97015

Open in the dashboard

General payments

$17

1 record reported · program year 2023

Research payments

$0

Paid to them · None reported · program year 2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kemble Green of Clackamas, OR is reported in the CMS Open Payments database as having received $17 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 4th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2023 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kemble Green
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Kemble Green were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Kemble Green Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $17 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program year 2023
  1. Janssen Pharmaceuticals, Inc $17 1 payment

Every payment, record by record

What the payments were for General payments · program year 2023
  1. Food and Beverage $17 1 payment
Products named General payments · program year 2023
  1. SPRAVATO $17 1 payment
  2. INVEGA SUSTENNA $17 1 payment
  3. INVEGA TRINZA $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

2,066

Median for Nurse Practitioner: 389

Drug cost

$103,922

Median for Nurse Practitioner: $21,885

Branded share of claims

22.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 78 $27,367
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $7,395
Entresto Sacubitril/Valsartan Brand 19 $6,399
Jardiance Empagliflozin Brand 18 $5,875
Oxycodone Hcl Generic 172 $5,418
Tresiba Flextouch U-100 Insulin Degludec Brand 15 $3,046
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $2,914
Renacidin Citric Ac/Gluconolact/Mag Carb Brand 14 $2,790
Pregabalin Generic 55 $2,399
Insulin Lispro Kwikpen U-100 Insulin Lispro Brand 22 $2,263

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$90,203

Medicare's payments for the services billed

Medicare patients

657

Average age 76

Services billed

1,618

344 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 61%
Arthritis 56%
Diabetes 47%
Heart failure 47%
Chronic kidney disease 45%
Alzheimer's or dementia 40%
Atrial fibrillation 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record